IBCSG 69-23 GeparPiPPa

  • A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer- GeparPiPPa.

    • Study Chair
      Prof. Dr. Sibylle Loibl

      Statistician
      Dr. Natalie Filmann, GBG Forschungs GmbH

      Trial Coordinator
      Dorene Polizzi

      Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      Targeted Accrual
      170

      Protocol Release Date 
      November 15, 2023

      Trial Activation Date 
      December 21, 2022

      First Patient In 
      Q1 2023

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login